Description

Cimzia (certolizumab pegol) is an injectable medication used to treat adults with the following conditions:

• Crohn’s disease
• Rheumatoid arthritis
• Active psoriatic arthritis
• Ankylosing spondylitis
• Non-radiographic axial ankylosing spondylarthritis with inflammatory signs
• Moderate-to-severe plaque psoriasis who are eligible to receive systemic therapy or phototherapy

Cimzia is available in either a single-dose vial containing 200 mg lyophilized powder or a single-dose prefilled syringe containing 200 mg/mL of solution.

Directions

Use Cimzia injection exactly as prescribed by your doctor. Your doctor will determine an appropriate treatment regimen for you based on the condition being treated. You or your caregiver should receive training on how to properly store, prepare, administer, and discard Cimzia.

Cimzia is for subcutaneous (underneath the skin) injection in the thigh or abdomen. Injection sites should be rotated with each injection.

Carefully read the medication guide that comes with your prescription for product use information. Tell your doctor or pharmacist about any questions or concerns you may have about the medication.

Needles and syringes should never be reused or shared with other people.

Ingredients

The active ingredient in Cimzia is certolizumab pegol.

Inactive ingredients in the lyophilized powder include lactic acid, polysorbate, and sucrose. Water for Injection is also used for mixing.

Inactive ingredients in the prefilled syringe include sodium acetate, sodium chloride, and Water for Injection.

Contraindications

Patients with a serious allergy to certolizumab pegol or to any of the other ingredients in Cimzia should not receive it.

Cautions

• Cimzia contains the following FDA Boxed Warning:
• The risk of serious infections that result in hospitalization or death including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections caused by other opportunistic pathogens is increased.
• If a patient develops a serious infection or sepsis, Cimzia should be stopped.
• A test for latent TB should be performed. Treatment for TB should be initiated before starting Cimzia if the test is positive.
• All patients should be monitored for active TB during treatment, even if their first latent TB test is negative.
• Children and adolescents who were treated with TNF blockers like Cimzia have developed potentially fatal lymphoma and other malignancies; therefore, Cimzia is not approved for use in pediatric patients.
• Before you begin treatment with Cimzia, inform your doctor of:
• All the prescription and over-the-counter medications you take
• Your allergies
• Your current health problems and past medical history
• Your pregnancy or breastfeeding status
• Cimzia is associated with the following warnings and precautions:
• Serious infections
• Malignancies, or cancers
• Heart failure
• Hypersensitivity reactions
• Hepatitis B virus reactivation
• Neurological reactions
• Bleeding problems
• Lupus-like syndrome
• Do not use Cimzia with Anakinra, abatacept, rituximab, or natalizumab, as the risk of serious infections is increased.
• Live vaccines should not be administered to patients receiving treatment with Cimzia.

Side Effects

Upper respiratory tract infection, rash, and urinary tract infection are common Cimzia side effects; however, other side effects may also occur. Immediately inform your doctor of any side effects that bother you or won’t go away.

You can buy Cimzia right here!

Reference

Cimzia. Smyrna, GA: UCB, Inc.; 2022.

About Dr. Savannah Muncy (Page Author)

Dr. Muncy (PharmD) studied science and education as an undergraduate before attending the Appalachian College of Pharmacy where she completed her PharmD in three years. She is currently using her pharmacy and healthcare expertise to write medical content for clients all around the world. She is focused on delivering the most current, accurate, and engaging information to healthcare professionals and patients. Read More....

Product Code : 11374